Mobia Medical filed terms for a $150 million initial public offering with pricing expected within 72 hours, entering a neuromodulation segment where three established manufacturers control 87% of the $8.2 billion global market. The San Diego–based company makes peripheral nerve stimulation devices that treat chronic pain without opioids, competing directly against Abbott's Proclaim and Medtronic's Intellis platforms.

The prospectus disclosed $42 million in trailing-twelve-month revenue, up 68% year-over-year, with gross margins at 71%—five points below Abbott's neuro division but seven points above the median for pre-profitable device makers. Mobia burned $38 million in cash over the same period. The company holds FDA clearance for its primary device but lacks the European CE Mark, which represents $2.1 billion in addressable market it cannot yet access. Lead underwriters are Jefferies and Piper Sandler.

The timing matters because healthcare IPOs raised $4.1 billion in the first quarter, the strongest start since 2021, but device makers specifically face tightening reimbursement schedules. CMS finalized a 3.1% cut to outpatient facility payments for neurostimulators effective July 1, which applies to all manufacturers but disproportionately pressures those without diversified revenue streams. Mobia derives 91% of revenue from a single product line, compared to 34% for Abbott's neuromodulation unit. Public investors will also compare Mobia's valuation to Nevro, which trades at 2.8x trailing revenue after cutting guidance twice in eight months.

The IPO gives Mobia capital to pursue the CE Mark and fund a pivotal trial for spinal cord stimulation, the larger adjacent market worth $3.4 billion annually. The trial requires 340 patients and 18 months of follow-up data, meaning commercialization would not occur before mid-2027. Without that expansion, Mobia competes in peripheral nerve stimulation—a $900 million niche where reimbursement remains inconsistent and physician adoption hinges on sales force density. Abbott employs 280 neuromodulation reps in the U.S. alone; Mobia disclosed a team of 47.

Allocators should watch the final share price against the bookbuild, expected to close Tuesday evening. A discount to the midpoint would signal institutional caution on single-product exposure and the European regulatory path. The post-IPO quiet period expires in 25 days, when analysts will publish models. CMS releases updated fee schedules for 2026 in November, which will clarify whether the reimbursement cuts are structural or a one-time adjustment. Mobia's lock-up expires 180 days after pricing, which puts insider selling in late Q4.